These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

89 related items for PubMed ID: 32306503

  • 21. Boost for vaginal microbicides against HIV.
    Lange JM, Karam M, Piot P.
    Lancet; 1993 Nov 27; 342(8883):1356. PubMed ID: 7901643
    [Abstract] [Full Text] [Related]

  • 22. Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children.
    Pienaar ED, Young T, Holmes H.
    Cochrane Database Syst Rev; 2006 Jul 19; (3):CD003940. PubMed ID: 16856025
    [Abstract] [Full Text] [Related]

  • 23. Beta-blockers for hypertension.
    Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Opie LH.
    Cochrane Database Syst Rev; 2017 Jan 20; 1(1):CD002003. PubMed ID: 28107561
    [Abstract] [Full Text] [Related]

  • 24. Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes.
    Notario-Pérez F, Ruiz-Caro R, Veiga-Ochoa MD.
    Drug Des Devel Ther; 2017 Jan 20; 11():1767-1787. PubMed ID: 28670111
    [Abstract] [Full Text] [Related]

  • 25. Safety, Acceptability and Adherence of Dapivirine Vaginal Ring in a Microbicide Clinical Trial Conducted in Multiple Countries in Sub-Saharan Africa.
    Nel A, Bekker LG, Bukusi E, Hellstrӧm E, Kotze P, Louw C, Martinson F, Masenga G, Montgomery E, Ndaba N, van der Straten A, van Niekerk N, Woodsong C.
    PLoS One; 2016 Jan 20; 11(3):e0147743. PubMed ID: 26963505
    [Abstract] [Full Text] [Related]

  • 26. Male circumcision for prevention of heterosexual acquisition of HIV in men.
    Siegfried N, Muller M, Deeks JJ, Volmink J.
    Cochrane Database Syst Rev; 2009 Apr 15; 2009(2):CD003362. PubMed ID: 19370585
    [Abstract] [Full Text] [Related]

  • 27. The relationship between vaginal ring use and intimate partner violence and social harms: formative research outcomes from the CHARISMA study in Johannesburg, South Africa.
    Hartmann M, Palanee-Phillips T, O'Rourke S, Adewumi K, Tenza S, Mathebula F, Wagner D, Ayub A, Montgomery ET.
    AIDS Care; 2019 Jun 15; 31(6):660-666. PubMed ID: 30309246
    [Abstract] [Full Text] [Related]

  • 28. Antibiotic therapy for pelvic inflammatory disease.
    Savaris RF, Fuhrich DG, Duarte RV, Franik S, Ross J.
    Cochrane Database Syst Rev; 2017 Apr 24; 4(4):CD010285. PubMed ID: 28436019
    [Abstract] [Full Text] [Related]

  • 29. Pregnancy incidence and risk factors among women participating in vaginal microbicide trials for HIV prevention: systematic review and meta-analysis.
    Musekiwa A, Muchiri E, Manda SO, Mwambi HG.
    PLoS One; 2013 Apr 24; 8(10):e77014. PubMed ID: 24130827
    [Abstract] [Full Text] [Related]

  • 30. U.S. Women Need the Dapivirine Ring, Too: FDA as Structural Barrier to HIV Prevention for Women.
    Gollub EL, Vaughan R.
    AIDS Educ Prev; 2022 Aug 24; 34(4):311-324. PubMed ID: 35994576
    [Abstract] [Full Text] [Related]

  • 31. Intravaginal practices, vaginal infections and HIV acquisition: systematic review and meta-analysis.
    Hilber AM, Francis SC, Chersich M, Scott P, Redmond S, Bender N, Miotti P, Temmerman M, Low N.
    PLoS One; 2010 Feb 09; 5(2):e9119. PubMed ID: 20161749
    [Abstract] [Full Text] [Related]

  • 32. The future role of rectal and vaginal microbicides to prevent HIV infection in heterosexual populations: implications for product development and prevention.
    Boily MC, Dimitrov D, Abdool Karim SS, Mâsse B.
    Sex Transm Infect; 2011 Dec 09; 87(7):646-53. PubMed ID: 22110117
    [Abstract] [Full Text] [Related]

  • 33. Utility of colposcopy in a phase 2 portion of a microbicide clinical trial of BufferGel and 0.5% PRO 2000 Gel.
    Chirenje ZM, Mâsse BR, Maslankowski LA, Ramjee G, Coletti AS, Tembo TN, Magure TM, Soto-Torres L, Kelly C, Hillier S, Karim A.
    J Int AIDS Soc; 2012 Aug 27; 15(2):17376. PubMed ID: 22944480
    [Abstract] [Full Text] [Related]

  • 34. Learning from the private sector: towards a keener understanding of the end-user for microbicide introduction planning.
    Lin AH, Breger TL, Barnhart M, Kim A, Vangsgaard C, Harris E.
    J Int AIDS Soc; 2014 Aug 27; 17(3 Suppl 2):19162. PubMed ID: 25224619
    [Abstract] [Full Text] [Related]

  • 35. Knowledge of HIV prevention and willingness to collaborate in vaginal microbicides trials-survey of Nigerian gynecologists.
    Musa J, Adamu IS, Muhammad Z, Egbodo C, Mohammed C.
    Niger J Med; 2012 Aug 27; 21(2):185-9. PubMed ID: 23311188
    [Abstract] [Full Text] [Related]

  • 36. Methodological lessons from clinical trials and the future of microbicide research.
    van der Straten A, Montgomery ET, Hartmann M, Minnis A.
    Curr HIV/AIDS Rep; 2013 Mar 27; 10(1):89-102. PubMed ID: 23184582
    [Abstract] [Full Text] [Related]

  • 37. Acceptability of the Dapivirine Vaginal Ring in Postmenopausal US Women.
    Shapley-Quinn MK, Laborde N, Luecke E, Hoesley C, Salata RA, Johnson S, Nel A, Soto-Torres L, Chen BA, van der Straten A.
    AIDS Patient Care STDS; 2022 Mar 27; 36(3):97-105. PubMed ID: 35289688
    [Abstract] [Full Text] [Related]

  • 38. Ring-ing in the Future: Participant and Male Partner Perspectives Regarding Future Use of the Dapivirine Vaginal Ring for HIV Prevention.
    Reddy K, Mathebula F, Katz A, Luecke E, Tenza S, Palanee-Phillips T, Garcia M, Mansoor LE, Naidoo S, Morar N, Chitukuta M, Tsidya M, Montgomery ET, MTN-032 Study team.
    AIDS Behav; 2022 Jun 27; 26(6):1923-1932. PubMed ID: 35064389
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.